On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
复制标题
DOI：
10.1016/j.vaccine.2003.12.036
复制
发表时间：
2004-11
期刊：
影响因子：
5.5
通讯作者：
J. Yannelli;J. M. Wroblewski
中科院分区：
文献类型：
--
作者：
J. Yannelli;J. M. Wroblewski
细胞免疫疗法（CI），正如我们现在所知道的，始于20世纪80年代初，使用淋巴因子激活的杀伤细胞（LAK），并发展到使用免疫特异性肿瘤浸润淋巴细胞（TIL）。TIL被证明对黑色素瘤特别有效，正是在这些试验中，我们了解到肿瘤免疫特异性的重要性。随着TIL识别的肿瘤抗原的鉴定和表征，我们现在看到这些抗原以各种形式构成疫苗的用途。研究人员正在使用肿瘤抗原单独或与树突状细胞（DC），人体最有效和最强大的抗原呈递细胞组合。治疗正在交付给许多不同类型的癌症患者，以对抗巨大的疾病，消除微转移性疾病，并提供记忆机制来对抗肿瘤复发。本文将详细介绍过去18年的情况，并介绍这种疗法的发展。许多人认为，随着不断发展，免疫疗法将提供第四种癌症治疗方式。
Cellular immunotherapy (CI), as we now know it, began in the early 1980s with the use of lymphokine-activated killer cells (LAK) and progressed to the use of the immunologically specific, tumor-infiltrating lymphocytes (TIL). TIL were shown to be particularly effective against melanoma and it was in these trials that we learned the importance of immunologic specificity for tumor. With the identification and characterization of tumor antigens recognized by TIL, we now see the use of these antigens in various forms constituting vaccines. Investigators are using tumor antigens alone or in combination with dendritic cells (DCs), the body’s most efficient and powerful antigen-presenting cell. Therapies are being delivered to many patients with different types of cancer in order to combat bulky disease, eliminate micro-metastatic disease, and provide a memory mechanism to fight tumor recurrence. This review will detail the past 18 years and present the developments that have been made in this therapy. Many believe that with continued development, immunotherapy will provide a fourth modality of cancer therapy.